40 results about "SKELETAL MUSCLE RYANODINE RECEPTOR" patented technology

Disclosed are mixtures and compositions for controlling invertebrate pests relating to combinations comprising (a) 3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, and its N-oxides, and suitable salts thereof

and a component (b) wherein the component (b) is at least one compound or agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondrial electron transport inhibitors, nereistoxin analogs, pyridalyl, flonicamid, pymetrozine, dieldrin, metaflumizone, biological agents, and suitable salts of the foregoing. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a mixture or composition of the invention.

The invention provides o-formammidotiazol-benzamide derivatives, and a preparation method and applications thereof. The o-formammidotiazol-benzamide derivatives have the chemical structure general formula represented by the formula I or the formula II. The invention discloses the structure general formula of the compounds, the synthesis method and the applications of the compounds as insecticides, acaricides and bactericides; the compounds are mixed with agriculturally acceptable auxiliary agents or synergistic agents for use in processing crafts of preparing the insecticides, the acaricides and the bactericides. The invention also discloses the applications of the compounds in combination with the commercial insecticides, the acaricides, the bactericides, anti-plant virus agents and plant activators for prevention and treatment of agriculture, forestry, horticulture plant diseases, insect attacks, acarus attacks and virus diseases, and the preparation method of the compounds.

The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

The invention provides a series of o-carboxamido benzamide derivatives, and preparation methods and applications thereof. The o-carboxamido benzamide derivatives have the chemical structure general formula represented as the formula I. The invention also discloses: the general formula and the synthetic method of the compounds and an application of the compounds in insecticides, acaricides and bactericides, and a process of preparing the acaricides and bactericides by mixing the compounds with agriculturally acceptable additives or synergists, and also discloses the combination of the compounds with commercial insecticides, acaricides, bactericides, anti-plant-viral agents and plant activators to prevent and treat diseases, pest damage, mite damage and viral diseases in the fields of agriculture, forestry and horticulture.

The present invention refers to non-human transgenic mammals, preferably rodents, or mice, which comprise a mutation in the gene encoding for the cardiac ryanodine receptor (RyR2).

Transgenic animals carrying the amino acid change R4496C in the RyR2 protein show a phenotype similar to that of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (OMIM: 604772). Further provided are methods for using these animals as in vivo model of Catecholaminergic Polymorphic Ventricular Tachycardia and RyR2 dependent arrhythmias, in drug screening and for understanding the molecular basis of RyR2 dependent arrhythmias.

Methods for identifying modulators of ryanodine receptors are disclosed. In preferred embodiments the activity of the ryanodine receptor is stimulated to a baseline level and the ability of a test compound to increase or decrease the baseline level indicates that the test compound is a modulator of ryanodine receptor activity.

The present invention provides a method of preventing or ameliorating pain in a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action causing said pain, an effective amount of a ryanodine antagonist, such as dantrolene, to inhibit or prevent pain.

The invention discloses a method and a special primer of the method for fast identifying the plutella xylostella ryanodine receptor gene mutation. The invention provides a specific primer combination, which consists of a single chain DNA (deoxyribonucleic acid) molecule shown as a sequence 1 of a sequence table, a single chain DNA molecule shown as a sequence 2 of the sequence table and a single-chain DNA molecule shown as a sequence 3 of the sequence table. The specific primer combination can be used for the following (a) or (b): (a) the specific primer combination can be used for identifying whether plutella xylostella generates the G4899E mutation of the ryanodine receptor gene or not, and the G4899E mutation of the ryanodine receptor gene refers to that an open reading frame of the ryanodine receptor gene is mutated into A from G in the 14696 locus nucleotide of the 5' tail end; and (b) the specific primer combination is used for the auxiliary identification of the resistance of plutella xylostella on bisamide pesticides. The specific primer combination and the application of the specific primer combination have the important significance in the aspects of monitoring the resistance gene frequency of plutella xylostella field populations on the bisamide pesticides and the bisamide pesticide resistance generation and development trend of the plutella xylostella field populations, timely regulating the plutella xylostella preventing and control strategy, guiding the reasonable pesticide use and delaying the resistance development.

The invention discloses a chilo suppressalis ryanodine receptor gene CsRyR, which is used for encoding a nucleotide sequence with a chilo suppressalis ryanodine receptor protein CsRyR, wherein the nucleotide sequence has at least 70 percent of homology with a nucleotide sequence shown as SEQ ID NO:1. The invention further discloses a protein encoded by using the chilo suppressalis ryanodine receptor gene CsRyR. The protein has an amino acid sequence shown as SEQ ID No:2. The chilo suppressalis ryanodine receptor gene CsRyR is used for screening and/or evaluating a substance for regulating and controlling the activity of a chilo suppressalis ryanodine receptor.

The invention discloses a bactericidal and insecticidal composition with ZJ10520 and ryanodine receptor insecticide. The bactericidal and insecticidal composition has the advantages that good bactericidal and insecticidal effects can be realized by the bactericidal and insecticidal composition, the bactericidal and insecticidal composition is low in medication frequency and medication cost, and the safety requirements on pesticide preparations can be met.

The invention discloses a molecular detection method and special primer for resistance of sesamia inferens to chlorantraniliprole, and provides a special primer composition which is composed of single-chain DNA molecules shown in the sequence 1, the sequence 2 and the sequence 3 in the sequence table. The special primer composition can be used for detecting whether gene G4924E mutation happens to an acting site, namely, a ryanodine receptor, of chlorantraniliprole or not. The gene G4924E mutation of the ryanodine receptor of sesamia inferens means that the 14771th nucleotide at the 5' end of an open reading frame of the ryanodine receptor gene mutates into A from G, and therefore resistance of sesamia inferens to chlorantraniliprole is detected. The special primer composition and application of the special primer composition have important significance in monitoring development trends of resistance of sesamia inferens field populations to chlorantraniliprole, guiding reasonable pesticide utilization, delaying resistance development, formulating resistance government policies and regulating prevention and control strategies in time.

The invention relates to a novel electrochemical luminescence kit for detecting an anti-Ryanodine receptor antibody (RyR) from a blood sample and a preparation method thereof. The prepared kit comprises a streptavidin-coated magnetic bead particle working solution, a biotin-labeled RyR antigen working solution, a terpyridyl-ruthenium-labeled anti-human IgG antibody working solution, a RyR-Ab calibration material and/or quality control material working solution, a tripropylamine-containing electrochemiluminescence substrate solution and a cleaning solution. A luminescence system of the preparedkit is electrochemiluminescence, a streptavidin-biotin biological reaction signal amplification system is utilized, the detection speed is high, the sensitivity is high, the linear range is wide, thedetection result repeatability is good; and accurate quantitative detection of RyR-Ab in blood can be realized.

Methods for inhibiting impaired neurogenesis and/or synaptogenesis in neurons in a subject with or suspected of having Alzheimer's Disease (AD), methods for improving and/or slowing the decline of cognitive function after onset of neuropathology and cognitive dysfunction, which neuropathology and cognitive dysfunction are caused by AD, methods for improving and/or slowing the decline of memory before onset of symptoms of AD, methods for increasing concentration and duration of dantrolene in the brain, and methods for improving and/or slowing the decline of memory after onset of symptoms of AD, the methods comprising intranasally administering to a subject in need thereof an amount of a pharmaceutical composition comprising dantrolene effective to inhibit over-activation of N-methyl-D-aspartate (NMVDA) receptor and/or ryanodine receptor (RyR). Methods further comprise administering a therapeutically effective amount of a glutamate receptor antagonist to the subject.

The present invention relates generally to novel peptides that are capable of modulating the activity of calcium channels in cardiac cells. More specifically, the present invention provides a method of modulating the activity of a cardiac calcium channel comprising contacting a cardiac ryanodine receptor (RyR2) with an amount of a fragment of a dihydropyridine receptor (DHPR) polypeptide sufficient to modulate the activity of said RyR2, and determining the activity of said calcium channel. The inventive method is useful for the treatment of a range of disorders and diseases associated with cardiac dysfunction, particularly those diseases and disorders involving reduced cardiac output and/or aberrant excitation-contraction coupling, calcium overload, or calcium leakage, in cardiac cells.

The present invention provides a method for the treatment of autosomal dominant Catecholaminergic Polymorphic Ventricular Tachycardia associated with mutations in the cardiac ryanodine receptor type 2 (RYR2) gene, by the use of an AAV mediated RNA interference approach to induce allele specific silencing of mutant mRNA.

When using a pharmaceutical composition for preventing or treating malignant hyperthermia, containing NAADP antagonists, of the present invention, malignant hyperthermia can be effectively prevented or treated through the inhibition of an oxygen consumption rate abnormal increase, which is associated with a ryanodine receptor (RYR) of skeletal muscles. In addition, the present invention can be used even after the onset of malignant hyperthermia and can inhibit an oxygen consumption rate abnormal increase even at concentrations lower than those of conventional agents for treating malignant hyperthermia, thereby enabling conventional agents for treating malignant hyperthermia to be replaced, and can be stably used, thereby being effectively usable in relevant industries. Furthermore, when using a skin regenerating composition, containing cADPR or NAADP antagonists, of the present invention, the skin can be protected from skin cell damage caused by UV-B of ultraviolet rays, and the skin regenerating composition has an excellent ability to recover and regenerate damaged skin and has no side effects on the same, thereby being usable in various forms such as a skin external preparation, a pharmaceutical composition, a cosmetic composition, and a food composition.

The composition for predicting Alzheimer's disease prognosis comprising a detection reagent that specifically binds to any one or more genes selected from the group consisting of (Nitric oxide synthase 1), Aph1B (Anterior pharynx defective 1 homolog B), Ryr3 (Ryanodine receptor 3), Atf6 (Activating transcriptional factor 6), Ip3r (Inositol trisphosphate receptor), Nep (Neprilysin), Cdk5 (cyclin dependent kinase 5) and Abad (Amyloid beta-binding alcohol dehydrogenase), a kit, and a method for providing information on Alzheimer's disease prognosis of the present invention can rapidly and accurately predict the prognosis of Alzheimer's disease, and can determine the prognosis for a drug by comparing the expression level before and after drug administration, so that an appropriate treatment direction can be determined according to the predicted prognosis. Therefore, they have an effect that can greatly contribute to the reduction of mortality due to Alzheimer's disease.

This disclosure concerns compounds and a method for modulating the activity of calcium ion channels, including Ca2+-induced (or Ca2+-activated) calcium release channels and conformationally coupled calcium release channels such as ryanodine receptors. Some of the compounds have a structure according to formula I, or a stereoisomer, tautomer, hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof.